Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alzheimer ph2b/3 ADCS-ADL was not statistically significant and it was hidden for 17 months yet Management (Missling) claimed all endpoints were successful.
If that’s not lying, then I don’t know what is.
Watch him mumble and stumble all over the place in May during ASM.
He’s not a good Liar and since he’s English as second language he will stutter more
Missling’s inaction regarding the release of ALZ data is revealing. He was counting on the Rett trial as well as the start of the schizophrenia trial to distract investors. When the Rett data fell short and the schizophrenia trial start did not impress, Missling was exposed.
The quarterly CC and the ASM should both be happening in May. Let’s see how Missling handles these events with the SP in the gutter.
let the shorty do they things..i'll do my.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
Well if you want for Missling to be exposed and stock price to crash to $0.00 then he could release now.
If he had amazing data results he would’ve shared it by now along with a Partnership.
Publish the Damm Alz data Dr. you won't get a peer review. Any nit wit knows that by now. You will have major litigation if you keep this data to yourself and continue to let the share price drop. Any idiot knows this!
Well, they can do “Anavex math” just like they did on December 2022 to claim trial
Success.
Peer review will take years as they try to decipher all the BS and claims Anavex states.
We need to get real and to recognize the potential of this new tool suite to generate fact based RWE-RWD which is reproduceable and (REAL WORLD) .
https://www.openpr.com/news/3473833/cognision-partners-with-anavex-for-phase-2-study-of-anavex-3-71.
Obviously the FDA is clueless on root cause(s) for CNS diseases after decades of beating the Amyloid dead horse they have back off...and now HOPE...is the plan.
This new partnership presents an opportunity to drive-evaluate for RWD-RWE and other hard CNS CAUSAL evidence. Begin finally to understand the key variables in the CNS (Central Nervous System). The FDA , "Problem solvers" have been shooting in a DARK ROOM w/ no real tools nor any evidence of the (ANY) analytical tool suite required to (AT LEAST) consistently reproduce results.
As Dr. W. Edwards Deming has famously said (50 years ago) , " The first step in solving a problem is recognizing that one exists". Unless and UNTIL the people in charge at FDA (or alternate regulatory bodies) agree they would not recognize a CNS SOLUTION (Even if they found it in their OATMEAL ) then they are kidding the world w/all their BS trials VAPORWARE logic.
The only starting point is w/ RWE-RWD and tools that are capable of building -supporting legitimate analytical methods and tools that are consistent and reproducible, 50+ years w/no clues is long enough. RWE and RWD will present a path to CNS (systems) certainty.
sum, when it was formed 5 years ago (ATH, please note, not "7"), Anavex was the principal driver to bring the original group of companies, which is why I've called it the "Anavex Consortium," regardless of the name established.
Obviously, with the new additions over the years, it has a stronger presence and I hope it has greater advancements in its future that will profit mankind ... and, of course, Anavex shareholders.
Miss Cleo Seeing "the Fib energies"?
It is rare I sell and even rarer that buy $AVXL. Each time aiming to improve my risk/reward and all the time being way in profit from selling at every irrational price spike with zero FOMO concerns. If something absolutely great should happen, I can always buy in with lower risk, but for a for smaller gain. I have no need to increase risk without a higher chance of a return.
What anyone might or might not do inspired by anything I post, is their own issue. I am not an investment advisor to anyone here. I don't care whether folks posting here owns $AVXL or not.
I never look in the rear mirror and think if only, cause its a useless waste of energy. I do however try to learn from my mistakes and of course the wonderful insights posted here.
I’m not sure what trial results you are looking at. And apparently the EMA disagrees with you. I think I’ll go with their view over yours.
Exactly. Nailed it.
Anavex 3-71 (formerly known as AF710b)
Yep, I like the 2.90 target. And 2.80.
But right now, I want to watch what price action does for any bounce at 3.40. It might give us some clues for direction from here.
Couldn't agree more. I did, however, buy more today in after hours. All the bent noses on this group occasionally lead me to forget why I believe in the fundamentals of the bio strategy of the Anavex treatment. And the gut feeling I acquired awhile back that 3-71 is "the one."
BTW, have you ever accidentally started reading posts in this iHub group from 2 or 3 years ago and, only after traversing through 20 or so posts, realize your were reliving a mirror of the future iHub discussion?
Submission is MILLIONS AND MILLIONS of pages according to Missling which 40 ppl on staff won’t be able to accomplish.
@Catdaddy, ... as far as maintaining my investment in Anavex, I'm still bullish, and still have a manageable position. I was looking to add a few thousand more shares if the price tumbled down like its doing, so I'm watching the price action for clues. I've been able to see what the downwave has been doing since the last major peak rolled over at 6.80. I got fooled a little when it bled down to 5.00, it looked like 5 could hold, so I bought a little there, and 4.70, and that was my last purchase. All the target steps going down from there, I watched and decided to pull away bids, target stepsin the 4's. I said back then, if the triple bottom 4.80 breaks down we could see an accelerated tumble into the 3's. And here we are now. I didn't buy the 4.00 target, and not today at the 3.40./// But having said all that, I'm watching even closer now, if 3.40 bounces, watch how high, or how weak, and would it roll over, just like 3.60 did, ...I would like the next targets from 3.25 to 3.00 to 2.75 I will buy some there. But managing the investment now, I'm always careful to buy in small pieces at a time, I'll add larger portions below 3 dollars. I will also need to sell a bunch if/when it gets back to 7 or 8 dollars, but that just what my investment needs for balance.
Amazing isnt it, 52 week low sitting on the next safe and effective SOC for Alzheimer’s. Gods watching!
$2.90 it is next bottom support.
You can't file anywhere with negative trial results!
So Tom, what are you doing at this point?
3.40 might be an ok place to start buying. I had placed some bids there a week ago, but a few days ago decided to pull them and wait for something closer to 3 dollars. It's a gamble . Sometimes I buy a step too soon, sometimes I wait too long and miss the bottom.
Hi Tom I grabbed a few shares today.
John k9uwa
Have been here since 2015 not likely to leave anytime soon!!
GLTA John
We all been scammed by Missling.
Told my family I apologized for investing in Anavex but Management 100% lied about results and many fell for that trap. We shouldn’t be ashamed but seek legal
Prosecution against Missling for defrauding investors.
It seems unlikely a favorable candidate to treat/cure Alzheimer Disease will appear any time soooon. I thought Blarcamesine had a running chance but not so much now. The rate of growth of incidences of Alzheimer Disease globally is concerning. The thought of creating generational wealth by investing here, under the failed leadership of Missling and his cronies for the past 9 years, I find appalling. My Bad! For now anyway, the best way to defeat Alzheimer Disease is to avoid it. India has one of the lowest rates of AD. Japan is another. This article seems a good starting place to start using food as medicine:
https://www.10faq.com/health/benefits-of-curcumin/?asid=a1_ch999&de=m&locale=en_US&sclid=0-24726&gad_source=1&gclid=CjwKCAjw26KxBhBDEiwAu6KXt_mPbFhCe_2PGr9MTexz9fcQejzKurDf56zOWI-8vKfrulJOsrsZTxoCLk4QAvD_BwE
Yesterday I said... watch the resistance zone around 3.80, to see if it gets hit and tumbles down to continue the downwave to lower targets, and this is what we got today. The 3.40 target step is hit. Remember the other day, I didn't think 3.60 would hold as a major bottom. This is bottom fishing time for AVXL investors and traders. Technically, 3.40 is a fairly big target because it's the 50% haircut from a major resistance peak at 6.80. The intermediate longer term chart picture, that started collapsing in January, from 10 dollar area, reversed up from the 4.80 zone and then peaked at 6.80. Here we are now at 3.40. I might pause here to watch and see whether a bounce happens now. But even if it bounces here , my sense is still looking for a continued downwave to reach what will become a cycle bottom. I don't think 3.40 is it. Fine tuning the chart picture, the timing of coming days, hedge fund rebalancing, lawsuit baloney news, cycle bottom price targets, ... we're in the old bottom zone again from 3 years ago. Bottom fishing can be tricky.
Sure, pal. So what is your hypothesis as to why they haven’t filed in Australia, considering their huge hoard of cash that you observed? I’m sure it’s a baseless negative assumption so let’s hear it. Or did you not have a point?
Money is not the only resource. There is also personnel, man hours and focus.
Maybe they will file in Australia. We don’t know.
I find it funny that as you celebrate that Investor and some others helped convince you to unload your Anavex shares that he and Frrol are adding to their holdings.
Now it is true that you did save half your remaining value at the time, but they are betting on a reversal and you appear to be happy to be on to other things.
Don’t be tempted to look in the rear view mirror. It may be best to not know how this all plays out.
You’re putting words in my mouth. I never said the trials were fabricated using crash test dummies or some other such nonsense.
Let’s revisit.
You claimed they are resource constrained and therefore focusing on Europe first. I countered that with 4+ years of cash, 40+ employees (plus consultants), and one small trial in the clinic that they surely have the resources to file in both Australia and Europe at the same time. I further suggested that filing in Australia might run in the low millions but surely would not break the piggy bank, and that the sooner they filed in Australia the sooner they could potentially start generating millions in revenues.
I’m not sure Blarcamesine would help you with maintaining focus on the issue at hand but I suspect this does not require medical intervention.
Your arguments and excuses are weak.
Yawn. Okay, you’re right. They haven’t filed in Australia because the trials were all fabricated, using crash test dummies. Is that what you want to hear?
Or is it that they are focusing on the larger European market first? I’ll let others decide. Enjoy whatever alternative conclusion you’re implying.
“They do not have unlimited resources.”
Four years of cash on hand and 40+ employees (plus consultants) and they don’t have the resources to file in Australia and Europe at the same time? It’s not like they’re running 10 clinical programs. That is just another excuse that doesn’t hold water. How much could it possibly cost to file in Australia? Maybe low millions? Certainly not tens of millions. And the sooner they filed in Australia the sooner they’d be generating millions in revenues in Australia.
On this MB It’s just one excuse after another. I’ve never seen anything like it.
Tootalljones the ADAS-COG end point (the one the FDA cares most about) was met with a 2.26 in 100 chance of it being due to chance and the reduction in brain volume loss was met with a 1 in 2,000 chance of it being due to chance, so I'm not sure why you are saying "no compelling evidence".
Probably tomorrow will be worse. But but but there is an 85% WGT chance so what could possibly go wrong?
raise your hand if you have been adding all the way down from 22 bucks? Raise both hands if you have been adding at 29 to 22? Imitate being financially fleeced at gun point. There is no compelling evidence that blarcasemine is effective enough to help any cns condition. And because the amoeba effect, I mean the placebo effect lasts up to two years in parkinsons and alheimers, it is probably questionable the drug has ever helped (and maintained its help), in a single trial patient of the roughly 600 total dosed trial subjects in the past dozen years. AND it is not just that the effect is either non existent< ineffective< and temporary< it is that the entire theory in this area of medicine is completely without a scientific basis> The notion that you can give a human a medicine which will restore the central nervous system is fanciful. The core CNS is not like the other organs of the human body, which compared to the CNS, are akin to bricks and mortar, whereas the processes of the CNS by comparison are like the Cern nuclear particle reactor or the JWS telescope. The whole theory of what anavex proposes is spun out of thin air. It is far more probably that there will be no drug such as is proposed by anavex, which will be effective over the next century, or two or three or 500 years. Which is why there are only a half dozen approved FDA drugs and none of them really work at all. After hundreds of candidates...THE whole theory of medicine or theories of medicine in the cns area is without a sound basis whatsoever> nobody and nothing can materially assist a damaged mind: the drug companies< the large one are hoping they get wildly lucky and then with pr and their influence with the Fda,, combined with dicey misdiagnosis by the companies of mild to moderate Alzheimer's in the trial group as a whole, AND DUE TO SYMPATHY FROM GOV REGULATORS, and low burdens of proof, they can get something not really helpful at all, approved nonetheless, and then start raking in the money. They can get in on the golden fleece. This whole proposal involves slippery standards, subjectivity and regulatory politics, and no objective proof whatsoever.
It is not a big issue for me whether they file the application next month or six months from now. I only care that it’s filed and accepted.
Go ahead and try to wait to buy, on your trade down strategy. Who cares? Personally, I will not sell any here. I’d be more likely to sell some investment shares if it was in the 20’s, as I did last time.
Those shares will wait until the outcome of the application process, whatever that may be.
So let’s see who’s right. They’ve had a window to work on the EMA application during the time that they are required to due to EMA rules. Not that they would otherwise submit it before the allowed time anyway.
Why haven’t they submitted in Australia? I assume they are prioritizing the larger markets first. They do not have unlimited resources. However, much of the work will be done for the first application so it will not have to be replicated.
“Keep your cool.”
You must be confusing me with someone else.
Bought some at the unpredicted LOD. I reckon the other side of index rebalancing will make that bit of dry power dryer.
Bas, you may use this advise and shared it with BSIG or was that just Sparky's thing?
Followers
|
1069
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
461946
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |